PubMed:34552510 JSONTXT

{"project":"yangbin123xm_800_3","denotations":[{"id":"T1","span":{"begin":289,"end":319},"obj":"DP"},{"id":"T10","span":{"begin":976,"end":979},"obj":"CI"},{"id":"T11","span":{"begin":1136,"end":1139},"obj":"CI"},{"id":"T12","span":{"begin":1322,"end":1325},"obj":"CI"},{"id":"T13","span":{"begin":38,"end":51},"obj":"CI"},{"id":"T2","span":{"begin":321,"end":324},"obj":"DP"},{"id":"T3","span":{"begin":458,"end":461},"obj":"DP"},{"id":"T4","span":{"begin":1411,"end":1414},"obj":"DP"},{"id":"T5","span":{"begin":68,"end":98},"obj":"DP"},{"id":"T6","span":{"begin":254,"end":267},"obj":"CI"},{"id":"T7","span":{"begin":269,"end":272},"obj":"CI"},{"id":"T8","span":{"begin":676,"end":679},"obj":"CI"},{"id":"T9","span":{"begin":737,"end":740},"obj":"CI"},{"id":"T14","span":{"begin":818,"end":825},"obj":"CI"},{"id":"T15","span":{"begin":851,"end":858},"obj":"CI"},{"id":"T16","span":{"begin":1015,"end":1022},"obj":"CI"},{"id":"T17","span":{"begin":1117,"end":1124},"obj":"CI"}],"text":"Efficacy of Intrauterine Perfusion of Cyclosporin A for Intractable Recurrent Spontaneous Abortion Patients With Endometrial Alloimmune Disorders: A Randomized Controlled Trial.\nOBJECTIVE: To explore the therapeutic efficacy of intrauterine perfusion of cyclosporin A (CsA) in intractable recurrent spontaneous abortion (RSA) patients with endometrial alloimmune dysfunction.\nMETHODS: This is a randomized controlled trial (RCT) of patients with intractable RSA with endometrial alloimmune disorders. A total of 201 women were enrolled, all of whom had at least 3 serial abortions and endometrial alloimmune dysfunction. Participants were randomly assigned to two groups. The CsA group (n = 101) received intrauterine infusion of 250 mg CsA on the 3rd and 7th days after menstruation for 2 menstrual cycles, while the placebo group (n = 100) received placebo. The birth of healthy, deformity-free babies was the main study outcome.\nRESULTS: In total, 75 (74.26%) women in the CsA group and 59 (59.00%) women in the placebo group gave birth to healthy babies [P = 0.01, OR = 2.01; 95% CI (1.10∼3.65)]. Compared to the placebo group, the CsA group had dramatically lower endometrial CD56+ cell and CD57+ cell concentrations at the luteal phase of the second menstrual cycle (P \u003c 0.05).\nCONCLUSION: Intrauterine perfusion of CsA was confirmed to be a promising approach for the treatment of intractable alloimmune RSA."}

{"project":"chenxin_473849_800_3","denotations":[{"id":"T1","span":{"begin":254,"end":267},"obj":"CI"},{"id":"T2","span":{"begin":38,"end":51},"obj":"CI"},{"id":"T3","span":{"begin":269,"end":272},"obj":"CI"},{"id":"T4","span":{"begin":676,"end":679},"obj":"CI"},{"id":"T5","span":{"begin":737,"end":740},"obj":"CI"},{"id":"T6","span":{"begin":976,"end":979},"obj":"CI"},{"id":"T7","span":{"begin":1136,"end":1139},"obj":"CI"},{"id":"T8","span":{"begin":1322,"end":1325},"obj":"CI"},{"id":"T9","span":{"begin":818,"end":825},"obj":"CI"},{"id":"T10","span":{"begin":851,"end":858},"obj":"CI"},{"id":"T11","span":{"begin":1015,"end":1022},"obj":"CI"},{"id":"T12","span":{"begin":1117,"end":1124},"obj":"CI"},{"id":"T13","span":{"begin":289,"end":319},"obj":"DP"},{"id":"T14","span":{"begin":68,"end":98},"obj":"DP"},{"id":"T15","span":{"begin":321,"end":324},"obj":"DP"},{"id":"T16","span":{"begin":458,"end":461},"obj":"DP"},{"id":"T17","span":{"begin":1411,"end":1414},"obj":"DP"}],"text":"Efficacy of Intrauterine Perfusion of Cyclosporin A for Intractable Recurrent Spontaneous Abortion Patients With Endometrial Alloimmune Disorders: A Randomized Controlled Trial.\nOBJECTIVE: To explore the therapeutic efficacy of intrauterine perfusion of cyclosporin A (CsA) in intractable recurrent spontaneous abortion (RSA) patients with endometrial alloimmune dysfunction.\nMETHODS: This is a randomized controlled trial (RCT) of patients with intractable RSA with endometrial alloimmune disorders. A total of 201 women were enrolled, all of whom had at least 3 serial abortions and endometrial alloimmune dysfunction. Participants were randomly assigned to two groups. The CsA group (n = 101) received intrauterine infusion of 250 mg CsA on the 3rd and 7th days after menstruation for 2 menstrual cycles, while the placebo group (n = 100) received placebo. The birth of healthy, deformity-free babies was the main study outcome.\nRESULTS: In total, 75 (74.26%) women in the CsA group and 59 (59.00%) women in the placebo group gave birth to healthy babies [P = 0.01, OR = 2.01; 95% CI (1.10∼3.65)]. Compared to the placebo group, the CsA group had dramatically lower endometrial CD56+ cell and CD57+ cell concentrations at the luteal phase of the second menstrual cycle (P \u003c 0.05).\nCONCLUSION: Intrauterine perfusion of CsA was confirmed to be a promising approach for the treatment of intractable alloimmune RSA."}